Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

The Oligonucleotide Synthesis, Modification and Purification Services Market is Expected to Grow at an Annualized Rate of over 10%, Claims Roots Analysis

This image opens in the lightbox

News provided by

Roots Analysis

16 Apr, 2020, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

The rapidly growing demand for oligonucleotides, coupled to complex manufacturing procedures and high capital investments required for setting up manufacturing facilities, has generated a range of new opportunities for custom manufacturers

LONDON, April 16, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of the "Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030" report to its list of offerings.

In fact, several big pharma companies are known to outsource more than half of their clinical-stage oligonucleotide manufacturing operations. Anticipating a sharp rise in demand, oligonucleotide manufacturers are increasingly consolidating their portfolios, building new capabilities and expanding their respective capacities, mostly through acquisitions, in order to gain a competitive edge.

To order this 300+ page report, which features 140+ figures and 190+ tables, please visit this link

Key Market Insights

Presently, there are 270+ trials evaluating a number of oligonucleotide-based interventions

Of these, around 40% are investigating the use of antisense oligonucleotides. Till date, more than 47,000 patients have been enrolled in ongoing / planned trials; majority of them being enrolled in Europe.

Over 80 companies claim to offer manufacturing services, at different scales of operation, for oligonucleotides 

The market landscape is currently dominated by the presence of small firms (1-50 employees), which represent close to 50% of the total number of industry stakeholders. This is followed by the larger and more established firms (~32%) and mid-sized players (~20%). More than 40% of service providers claim to operate at all scales of operation.

More than 70% service providers focus on production of oligonucleotides for research and diagnostic applications 

However, several players are shifting their focus onto manufacturing oligonucleotides for therapeutic use. It worth highlighting that close to 20% of service providers engaged in this domain claim to offer manufacturing services for research, diagnostic, and therapeutic applications.

Partnership activity has increased at a CAGR of over 60% within this domain, since 2014

Majority of the agreements (40%) were signed to offer manufacturing services to oligonucleotide-based product developers, followed by mergers / acquisitions (21%), aimed at the consolidation of existing service portfolios.

Multiple expansion initiatives were undertaken by service providers, between 2014 and 2019

Over 45% of such initiatives were reported to be focused on expanding manufacturing-related capabilities, followed by building new facilities (25%).

Demand for oligonucleotides is anticipated to grow at a CAGR of 13.3%, during 2020-2030

Given the fact that several oligonucleotide-based drug products were approved in the last 3-4 years, the commercial demand for oligonucleotides is high. Interestingly, over 65% of the estimated commercial demand was observed to have generated from products intended for treating neuromuscular disorders.

The US and EU have emerged as major oligonucleotide manufacturing hubs, both in terms of number of facilities and installed capacity

More than 55 oligonucleotide manufacturers were observed to have facilities in the US and EU. At present, the annual, installed manufacturing capacity in these regions is estimated to represent around 75% of the available global capacity. This is primarily driven by players with commercial scale expertise / capabilities.

Antisense oligonucleotides and siRNAs are anticipated to capture over 70% of the market share. by 2030

Interestingly, the manufacturing services market for miRNAs and other novel oligonucleotides is anticipated to grow at a relatively faster rate during the next decade.

To request a sample copy / brochure of this report, please visit this link 

Key Questions Answered

  • Who are the leading manufacturers of oligonucleotides for use in research, diagnostic and therapeutic applications?
  • What are the preferred custom synthesis, modification and purification methods used for oligonucleotides?
  • What are the key challenges faced by oligonucleotide manufacturers?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What are the recent expansion initiatives undertaken by service providers within this domain?
  • What is the annual clinical and commercial demand for oligonucleotides?
  • What is the current, installed manufacturing capacity for oligonucleotides?
  • What percentage of oligonucleotide manufacturing operations are outsourced to service providers?
  • What are the opportunities in emerging markets for oligonucleotide manufacturing?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to oligonucleotide manufacturing?

The ~USD 3.0 billion financial opportunity (by 2030) within the oligonucleotide synthesis, modification and purification services market has been analyzed across the following segments:

  • Application
    • Research and diagnostics
    • Therapeutics
  • Type of oligonucleotide manufactured
    • Antisense
    • miRNA
    • siRNA
    • Other oligonucleotides
  • Scale of Operation
    • Preclinical / Clinical
    • Commercial
  • Company Size
    • Small
    • Mid-sized
    • Large
  • Target Therapeutic Area
    • Oncological disorders
    • Ophthalmic disorders
    • Metabolic disorders
    • Autoimmune disorders
    • Other therapeutic areas
  • Key geographical regions
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the world

The report features inputs from the eminent industry stakeholders, according to whom the oligonucleotide manufacturing services market is primarily driven by the increasing demand for such molecules for use in diagnostic and therapeutic applications. The report includes detailed transcripts of discussions held with the following experts:

  • Joachim Bertram (Chief Scientific Officer and Managing Director, IBA Lifesciences)
  • Tobias Pohlmann (Founder and Managing Director, BianoScience)

The research covers detailed profiles, featuring a brief company overview, its financial information (if available), information related to its service portfolio, manufacturing facilities, details on partnerships, recent developments (expansions), and awards received by the firm, as well as an informed future outlook.

  • Agilent Technologies
  • Ajinomoto Bio-Pharma Services
  • BioSpring
  • CordenPharma
  • Integrated DNA Technologies
  • Kaneka Eurogentec
  • LGC Biosearch Technologies
  • Microsynth
  • Nitto Denko Avecia
  • Sigma Aldrich
  • Thermo Fisher Scientific
  • Trilink Biotechnologies

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html  or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.  China Biopharmaceutical Contract Manufacturing Market, 2020-2030

2.  China Pharmaceutical Contract Manufacturing Services Market, 2020-2030

3.  Pharmaceutical Continuous Manufacturing Market, 2020-2030

4.  Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030

5.  Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030

Contact:

Gaurav Chaudhary
+1 (415) 800-3415
+44 (122) 391-1091
Gaurav.Chaudhary@rootsanalysis.com

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.